Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
All News
Headline News
Press Releases
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
From VITRAC Therapeutics, LLC
Via Business Wire
Cyxtera Takes Next Step to Implement Restructuring Support Agreement
From Cyxtera
Via Business Wire
Tickers CYXT
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
Tickers NTRA
Blue Yonder and nConnect Group Successfully Implement WMS Solution for Team Global Express in New Zealand
From Blue Yonder
Via Business Wire
BrainChip and Lorser Industries to Develop Neuromorphic Computing Systems for Software-Defined Radio Devices
From BrainChip Holdings Ltd
Via Business Wire
Tickers ASX:BRN BCHPY BRCHF
Relay Robotics Introduces Relay2, The New High-Capacity Hotel Delivery Robot
From Relay Robotics, Inc.
Via Business Wire
Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care
From Massive Bio
Via Business Wire
Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer
From Ontada
Via Business Wire
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Tickers SMMT
Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice
From Nucleai
Via Business Wire
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Drive Shack Inc. Modifies Tax Benefits Plan
From Drive Shack Inc.
Via Business Wire
Tickers DSHK
Mountain Valley Pipeline To Proceed
From Equitrans Midstream Corporation
Via Business Wire
Tickers ETRN
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing
From GRAIL, LLC
Via Business Wire
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
From GRAIL
Via Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Tickers S
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
From Exai Bio
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Tickers CYT
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
From Massive Bio
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit
From Patient Safety Movement Foundation
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Tickers DZSI
SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Tickers S
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.